Dermatol. praxi. 2020;14(4):193-196 | DOI: 10.36290/der.2020.036

Acquired perforating disorders

MUDr. Miriam Kantová
I. dermatovenerologická klinika FN u sv. Anny v Brně a LF MU

Acquired perforating disorders represent a group of a rare dermatosis characterized by transepithelial extrusion of collagen and elastic fibers. The disease begins mainly in the adulthood and it does not depend on the gender. It is most associated with diabetes mellitus and renal failure. Eleven percent of patients on hemodialysis have some perforating disorder in comparison with the rest of the population. The main complication being pruritus can lead to formation of secondary eflorescention or impetiginisation. In a big group it can cause insomnia because of the itching lesion. In this article we describe the main characteristic, etiopathogenesis, diagnostic and therapy of this rare disease.

Keywords: acquired perforating disorders, Kobner phenomenon, transepidermal elimination.

Published: November 20, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kantová M. Acquired perforating disorders. Dermatol. praxi. 2020;14(4):193-196. doi: 10.36290/der.2020.036.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Harbaoui S, Litaiem N. Acquired Perforating Dermatosis [online]. 2020. [cit. 2020-7-8]. Dostupné na: https://www.ncbi.nlm.nih.gov/books/NBK539715/.
    2. McKee PH, Calonje E, Grantner SR. Pathology of the skin. Vol. 1. London: Elsevier 2005: 1683 s.
    3. Fernandes K, Lima L, Guedes J, et al. Acquired perforating dermatosis in a patient with chronic renal failure. An Bras Dermatol. 2016; 58(5 Supp l): 10-13. Go to original source... Go to PubMed...
    4. Goldsmiht LA, Katz SI, Gilchrest BA, et al. Fitzpatrick's Dermatology in General Medicine. Eight Edition. United States of America: The Mc Graw‑Hill Companies 2012: 727-731.
    5. Tilz H, Becker JCH, Legat F, et al. Allopurinol in the treatment of acquired reactive perforating collagenosis. J An Bras Dermatol. 2013; 88(1): 94-97. Go to original source... Go to PubMed...
    6. Hong SB, Park JH, Ihm CHG, et al. Acquired Perforating Dermatosis in Patients with Chronic Renal Failure and Diabetes Mellitus. J Koren Med Sci. 2004; 19(2): 283-288. Go to original source... Go to PubMed...
    7. Caley MP, Martins VLC, O'Toole EA. Metalloproteinases and Wound Healing. Adv Wound Care (New Rochelle). 2015; 4(4): 225-234. Go to original source... Go to PubMed...
    8. Mullins TB, Sickinger M, Zito PM. Reactive Perforating Collagenosis [online]. 2020. [cit. 2020-7-7]. Dostupné na: https://www.ncbi.nlm.nih.gov/books/NBK459214/.
    9. Lo YP, Snehal D, Deng LH, et al. Successful treatment of acquired reactive perforating collagenosis induced by pregnancy with allopurinol: A case report with review of literature. Dermatologica Sinica. 2019; 37(3): 162-165. Go to original source...
    10. Kim RH, Kwa M, Adams S, Meehan SA, Stein JA. Giant acquired reactive perforating collagenosis in a patient with diabetes mellitus and metastatic breast carcinoma. JAAD Case Rep. 2016 Jan 14; 2(1): 22-24. Go to original source... Go to PubMed...
    11. Falco OB, Plewig G, Wolff HH, et al. Dermatology. Third Edition. Germany: Springer - Verlag 2013: 500-551.
    12. Hall BJ, Chisholm C, Vandergriff, et al. Diagnostic Pathology: Nonneoplastic Dermatopathology E - Book. Edition 2. Canada: Elsevier Health Sciences 2016: 243-244.
    13. Calonje JE, Brenn T, Lazar A, et al. McKee's Pathology of the Skin 4th Edition. The United Kingdom: Elsevier Saunders 2012: 318.
    14. Patterson JW. Weedon's Skin Pathology E‑Book Edition 5. United States of America: Elsevier Limited 2019: 507.
    15. Marks RM, Knight AG, Laides P. Atlas of Skin Pathology. Netherland: Springer Science 2012: 79.
    16. Dames WD, Elston JD, Berger T. Andrew's Diseases of the Skin E‑Book: Clinical Dermatology, Edition 11. London: Elsevier Health Sciences 2011: 764.
    17. Lukács J, Schliemann S, Elsner P. Behandlung der erworbenen reaktiven perforierenden Dermatose - eine systematische Übersicht [online]. 2018. [cit. 2020-7-9]. Dostupné na: https://onlinelibrary.wiley.com/doi/full/10.1111/ddg.13561_g.
    18. Forouzandeh M, Maderal A. The novel use of mu‑opioid receptor antagonism for the treatment of refractory pruritus in Kyrle's disease [online]. 2019. [cit. 2020-7-9]. Dostupné na: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938818/.
    19. Shiraishi K, Masunaga T, Tohyama M, et al. A Case of Perforating Folliculitis Induced by Vemurafenib [online]. 2018. [cit. 2020-7-6]. Dostupné na: https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3059.
    20. Ngan V, Writer S. Elastosis perforans serpiginosa [online]. 2003. [cit. 2020-7-9]. Dostupné na: https://dermnetnz.org/topics/elastosis‑perforans‑serpiginosa/.

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.